摘要
目的分析超说明书使用替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌肺炎安全性。方法随机选定2016年2月—2018年2月本院收治的肺炎患者110例作为研究对象。采用随机数字表法分组,将其分为对照组、试验组,每组样本容量55例,常规用药为对照组,超说明书使用为试验组。对比两组患者的临床疗效、不良反应。结果与对照组比较,试验组患者的临床疗效较高,差异具有统计学意义(P<0.05);两组患者的不良反应发生率对比,差异不具有统计学意义(P>0.05)。结论替加环素、头孢哌酮舒巴坦超说明书使用可有效改善多重耐药鲍曼不动杆菌肺炎患者的病情,但不会增加不良反应。
Objective To analyze the safety of multidrug-resistant Acinetobacter baumannii pneumonia in combination with the use of tigecycline and cefoperazone sulbactam in the supercardiomy. Methods 110 cases of pneumonia in our hospital from February 2016 to February 2018 were randomly selected as the research subjects. They were divided into control group and experimental group by random number table method, with 55 cases in each group. The conventional medication was used as the control group. The super instruction was used as the test group. The clinical efficacy and adverse reactions of the two groups were compared. Results Compared with the control group, the clinical efficacy of the experimental group was higher, and the difference was statistically significant（P 〈0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（P 〉0.05）. Conclusion The use of tigecycline and cefoperazone sulbactam in the over-specific instructions can effectively improve the condition of patients with multi-drug resistant acinetobacter baumannii pneumonia, but it will not increase adverse reactions and is worth learning from.
作者
沈晓雁
范朝辉
SHEN Xiaoyan;FAN Zhaohui(Department of Pharmacy,Xiaonan District Maternal and Child Health Hospital,Xiaogan Hubei 432000,China)
出处
《中国继续医学教育》
2018年第20期138-139,共2页
China Continuing Medical Education
关键词
替加环素
头孢哌酮舒巴坦
鲍曼不动杆菌
肺炎
安全性
分析
tigecycline
cefoperazone sulbactam
acinetobacter baumannii
pneumonia
security
analysis
